ICIG’s CordenPharma Group today announced the closing of a syndicated loan of EUR 60 million.
CordenPharma Group successfully closed its first syndicated loan on advantageous terms. The amount of EUR 60 million is split into a term loan and revolving credit facility with the option of a further increase. Funds can be used for general corporate purposes and acquisitions. The facilities create a solid basis to achieve the growth plans of the group.
The inaugural financing was co-ordinated by ING Bank in a syndicate that also includes Bayerische Landesbank and Intesa Sanpaolo as Mandated Lead Arrangers & Bookrunners.
About CordenPharma Group
CordenPharma Group, the Pharmaceuticals platform of International Chemical Investors Group (ICIG), is a full-service provider in Contract Development & Manufacturing (CDMO) of APIs, Drug Products and associated Packaging Services. With a network of ten facilities in Europe and the United States, CordenPharma generates sales in excess of EUR 350 million with more than 1,700 employees. For more information about CordenPharma: www.cordenpharma.com.
About International Chemical Investors Group
International Chemical Investors is a privately owned industrial group with sales in excess of EUR 2 billion and more than 6,000 employees worldwide. ICIG is focusing on three main platforms: Pharmaceuticals under the CordenPharma brand, Fine Chemicals under the WeylChem brand and Chlorovinyls under the VYNOVA brand. Since inception in 2004, ICIG has acquired 25 independent chemicals and pharmaceutical businesses in Europe and the United States, all of which have origins in major global chemical or pharmaceutical corporations. For more information about International Chemical Investors Group: www.ic-investors.com.
Contact:
International Chemical Investors Group
Sibel Cumcu
Phone: +49 69 506 999 0
Email: Info@ic-investors.com
GERMANY